Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/42

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/140696CONSTRUCTS COMPRISING SINGLE DOMAIN VHH ANTIBODIES AGAINST SARS-CoV-2
WO 30.06.2022
Int.Class A61K 39/42
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
42viral
Appl.No PCT/US2021/065138 Applicant LUMEN BIOSCIENCE, INC. Inventor ROBERTS, James
The present disclosure relates to single domain antibodies ("VHHs") against SARS-CoV-2, as well as to polypeptides comprising one or more of such VHHs. The disclosure also relates to nucleic acids encoding such VHHs and polypeptides; to methods of preparing such VHHs and polypeptides; to host cells expressing or capable of expressing such VHHs or polypeptides; to compositions comprising such VHHs, polypeptides, nucleic acids or host cells; and to uses of such VHHs, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes.
2.WO/2022/135139NUCLEIC ACID CONSTRUCT FOR AIDS GENE THERAPY
WO 30.06.2022
Int.Class C12N 15/63
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
Appl.No PCT/CN2021/136153 Applicant KANGLIN BIOTECHNOLOGY (HANGZHOU) CO., LTD Inventor WU, Haoquan
Provided is a nucleic acid construct for AIDS gene therapy. The nucleic acid construct comprises multiple polynucleotides encoding single chain variable region fragments of an anti-AIDS neutralizing antibody, and polynucleotides encoding immunoglobulin Fc fragments; the single chain variable region fragments of the anti-AIDS neutralizing antibody comprise a single chain variable region fragment capable of specifically binding to HIV, and a single chain variable region fragment capable of specifically binding to a CD4 receptor. The construct can be used for gene therapy of AIDS caused by HIV infection, and the construct can be used for expressing an amphotropic/polytropic neutralizing antibody having broad-spectrum and high-efficiency neutralizing activity in vitro and in vivo and can be used for clinical research and new drug development of AIDS gene therapy drugs delivered by recombinant viral or non-viral vectors.
3.WO/2022/133547CORONAVIRUS VACCINE
WO 30.06.2022
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/AU2021/051553 Applicant THE UNIVERSITY OF MELBOURNE Inventor GODFREY, Dale Ian
The present invention relates to chimeric and fusion proteins and their compositions, and the use of such proteins and compositions in the prevention and/or treatment of coronavirus infections, or respiratory diseases or conditions associated with coronavirus infections.
4.WO/2022/133545SARS-COV-2 ANTIBODIES
WO 30.06.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/AU2021/051550 Applicant GARVAN INSTITUTE OF MEDICAL RESEARCH Inventor MAZIGI, Ohan
The present disclosure is directed to isolated or recombinant antigen binding proteins, such as antibodies, which bind to coronavirus spike (S) protein receptor binding domain (RBD), including S protein RBD from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The present disclosure is also directed to the use of the isolated or recombinant proteins as therapeutic, prophylactic and/or diagnostic agents for respiratory conditions associated with coronavirus infection, such as infection by SARS-CoV-2. The present disclosure is also related to nucleic acid sequences which encode said antigen binding proteins and their expression in recombinant host cells.
5.WO/2022/132987METHOD OF MEASURING LEVELS OF NEUTRALIZING ANTIBODIES OF SARS-COV-2
WO 23.06.2022
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/US2021/063646 Applicant YOUHEALTH BIOTECH, LIMITED Inventor ZHANG, Kang
A method of assessing the immunity of a human subject against SARS-CoV-2 includes measuring the levels or concentrations of neutralizing antibodies of the subject in a bodily fluid of the subject that block the interaction between the receptor binding domain (RBD) of the viral spike protein of SARS-CoV-2 and the ACE2 cell surface receptor using a recombinant RBD or a portion thereof as an antigen to titrate the levels or concentrations of the neutralizing antibodies in the bodily fluid. A detection kit for detecting the levels or concentrations of neutralizing antibodies of the subject is also provided.
6.WO/2022/132641HUMAN IGE MONOCLONAL ANTIBODIES TO ANTIBODIES TO ALPHA-GAL (GALACTOSE-A-1,3-GALACTOSE) AND USES THEREFOR
WO 23.06.2022
Int.Class A61K 38/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
10Peptides having 12 to 20 amino acids
Appl.No PCT/US2021/063107 Applicant VANDERBILT UNIVERSITY Inventor SMITH, Scott, A.
The present disclosure is directed to human IgE antibodies and fragments thereof binding to galactose-α-1, 3-galactose, a known red meat allergen, and methods for use thereof.
7.WO/2022/127793RESPIRATORY SYNCYTIAL VIRUS-SPECIFIC BINDING MOLECULE
WO 23.06.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2021/138018 Applicant TRINOMAB BIOTECH CO., LTD. Inventor LIAO, Huaxin
The present disclosure relates to a respiratory syncytial virus (RSV)-specific binding molecule and an application thereof. Further provided in the present disclosure are a method for preparing the molecule, and an application of the molecule in the preparation of a product that specifically binds to an RSV surface glycoprotein fusion protein and in the preparation of an RSV vaccine, and other such aspects.
8.20220195015NEUTRALIZING ANTI- SARS-COV-2 ANTIBODIES
US 23.06.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No 17519173 Applicant The Rockefeller University Inventor Michel Nussenzweig

This disclosure provides novel broadly neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection against SARS-CoV-2 infections.

9.WO/2022/127739ANTIGEN-BINDING PROTEIN SPECIFICALLY BINDING TO SARS-COV-2
WO 23.06.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/CN2021/137499 Applicant JECHO BIOPHARMACEUTICALS CO., LTD Inventor ZHU, Jianwei
Provided is an isolated antigen-binding protein specifically binding to SARS-CoV-2, a method for preparing the antigen-binding protein, and the pharmaceutical use thereof. The antigen-binding protein comprises at least one CDR in a light chain variable region VL, wherein the CDR comprises an amino acid sequence as shown in SEQ ID NO: 95.
10.WO/2022/125378COMBINATION THERAPY
WO 16.06.2022
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/US2021/061697 Applicant VIIV HEALTHCARE COMPANY Inventor HONG, Zhi
The present invention relates to a combination of cabotegravir or a pharmaceutically acceptable salt thereof and a gp120 binding protein. The present invention also provides a method of treatment human immunodeficiency virus (HIV) with the co-administration of a therapeutically effective amount of cabotegravir or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of a gp120 binding protein.